Reduction of thrombus formation on dialyser membranes by aspirin and RA 233.
D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001772:Blood Cell Count; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004983:Ethanolamines / Q000627:therapeutic use; D005165:Factor V / Q000032:analysis; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007688:Kidneys, Artificial / Q000009:adverse effects; D008297:Male; D010880:Piperidines / Q000627:therapeutic use; D010919:Placebos; D010958:Plasminogen / Q000032:analysis; D010973:Platelet Adhesiveness / Q000187:drug effects; D011743:Pyrimidines / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects*; D013927:Thrombosis / Q000517:prevention & control*
D004983:Ethanolamines; D010880:Piperidines; D010919:Placebos; D011743:Pyrimidines; D005165:Factor V; D010958:Plasminogen; D006493:Heparin; D001241:Aspirin